NCT02194829View on ClinicalTrials.gov

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 19, 2014

Primary Completion Date

June 3, 2021

Study Completion Date

December 21, 2022

Conditions
Metastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v6 and v7Stage IV Pancreatic Cancer AJCC v6 and v7Unresectable Pancreatic Carcinoma
Interventions
DRUG

AZD1775

Given PO

DRUG

Gemcitabine

Given IV

DRUG

Nab-paclitaxel

Given IV

Trial Locations (5)

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

37232

Vanderbilt University/Ingram Cancer Center, Nashville

44106

Case Western Reserve University, Cleveland

60611

Northwestern University, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02194829 - Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter